What Turbine does
Turbine builds an AI-powered virtual biology platform that simulates cancer cell behavior and drug responses, helping pharmaceutical companies find and validate new drug targets before costly wet-lab experiments. The company says its Virtual Lab runs tens of millions of simulations daily across more than 1,400 oncology cell lines and 1,200+ drugs and payloads. Its pharma partners and customers include AstraZeneca, Merck/MSD, Bayer, Ono Pharmaceutical and Cancer Research Horizons. Turbine, founded by Hungarian scientists, is based in Budapest with an additional office in London.
Turbine is a healthcare tool on Falcoscan. AI platform that simulates cancer biology to accelerate drug discovery. Falcoscan rates Turbine with an Opportunity score of 84/100, a Saturation score of 11/100, and a Wrapper-risk score of 9/100. Market signal: rising. Turbine is founded in 2015, currently at Series_b stage. Pricing: Paid.